These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20980285)

  • 41. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
    Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis.
    Choy E
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii68-9. PubMed ID: 14532153
    [No Abstract]   [Full Text] [Related]  

  • 43. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A clinical perspective of rheumatoid arthritis.
    Scherer HU; Burmester GR
    Eur J Immunol; 2009 Aug; 39(8):2044-8. PubMed ID: 19672900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis.
    Kanbe K; Nakamura A; Inoue Y; Hobo K
    Rheumatol Int; 2012 Sep; 32(9):2669-74. PubMed ID: 21789615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis.
    Malaviya AP; Ledingham J; Bloxham J; Bosworth A; Buch M; Choy E; Cope A; Isaacs J; Marshall D; Wright G; Ostör AJ; ;
    Rheumatology (Oxford); 2014 Jul; 53(7):1344-6. PubMed ID: 24821853
    [No Abstract]   [Full Text] [Related]  

  • 47. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.
    Nishina N; Kikuchi J; Hashizume M; Yoshimoto K; Kameda H; Takeuchi T
    Ann Rheum Dis; 2014 May; 73(5):945-7. PubMed ID: 24336338
    [No Abstract]   [Full Text] [Related]  

  • 48. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study.
    Hashimoto J; Garnero P; van der Heijde D; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Yoshikawa H; Nishimoto N
    Mod Rheumatol; 2011 Feb; 21(1):10-5. PubMed ID: 20574648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-interleukin-6 therapy in rheumatoid arthritis.
    Woodrick R; Ruderman EM
    Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis.
    Alfonso-Cristancho R; Armstrong N; Arjunji R; Riemsma R; Worthy G; Ganguly R; Kleijnen J
    Clin Rheumatol; 2017 Jan; 36(1):25-34. PubMed ID: 27726046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks.
    Yokoe I; Nishio S; Sato H; Kobayashi H
    Mod Rheumatol; 2011 Dec; 21(6):710-4. PubMed ID: 21656090
    [No Abstract]   [Full Text] [Related]  

  • 52. The clinical efficacy of tocilizumab in rheumatoid arthritis.
    Mircic M; Kavanaugh A
    Drugs Today (Barc); 2009 Mar; 45(3):189-97. PubMed ID: 19436841
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA).
    Kobayashi K; Okamoto Y; Inoue H; Usui T; Ihara M; Kawamata J; Miki Y; Mimori T; Tomimoto H; Takahashi R
    Intern Med; 2009; 48(15):1307-9. PubMed ID: 19652436
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
    Nishimoto N; Hashimoto J; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Murata N; van der Heijde D; Kishimoto T
    Ann Rheum Dis; 2007 Sep; 66(9):1162-7. PubMed ID: 17485422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Anti-interleukin-6 receptor antibody therapy--from bedside to bench].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2006 Oct; 29(5):289-94. PubMed ID: 17075187
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis.
    Hirabayashi Y
    Mod Rheumatol; 2021 Jan; 31(1):70-79. PubMed ID: 32342712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci AB; Feist E; Burmester GR
    BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein.
    Clarivet B; Robin P; Pers YM; Ferreira R; Lebrun J; Jorgensen C; Hillaire-Buys D; Brés V; Faillie JL
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1413-1414. PubMed ID: 27457374
    [No Abstract]   [Full Text] [Related]  

  • 59. [Rheumatoid arthritis and ankylosing spondylitis-rheumatologic highlights 2009].
    Dudler J
    Rev Med Suisse; 2010 Jan; 6(232):141-2, 144. PubMed ID: 20170034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Tocilizumab in rheumatoid arthritis. Interleukin 6 as a new target].
    Heinzl S
    Med Monatsschr Pharm; 2008 Dec; 31(12):450-3. PubMed ID: 19133593
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.